The Animal Drug Compounding Market is meant to grow on a splendid note in the next decade. With technology creeping in, the time-consuming routine is being taken over by telehealth/e-Health records. Almost everything that was happening in person has been taken over by remote monitoring. This has helped in transcending the geographical barriers as well. These would be the trends concerning the Animal Drug Compounding Market in the future.
Animal drug compounding is the procedure of combining, mixing, or modifying ingredients to create a medication customized to the needs of animals, and these medications can be extremely useful in veterinary medicine. Growing demand for such customized medication has led the market to grow significantly in the past and reach a valuation of US$ 1.84 Bn in 2021. The market for animal drug compounding is projected to register 8.2% CAGR and top a valuation of US$ 4 Bn by 2031.
Central nervous system inflammation is found to be the most common reason that causes neurological disorders in dogs and cats. High cost associated with branded animal drugs, especially for those employed in the treatment of neoplastic and immune-mediated diseases, is cited as one of the important factors by veterinarians leading to increasing number of compounded drug prescriptions. Also, the overall expenditure for animal medical care for many pet owners is completely out of pocket, and very limited animal species are covered under medical insurance policies.
Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/12871
As such, a large number of veterinarians are prescribing compounded versions of approved branded drug. These include chlorambucil for lymphoma, and drugs for atopic dermatitis and fungal infection. Thus, high demand for CNS drugs will drive animal drug compounding market growth over the coming years.
Company Profiles:
- Hoye’s Pharmacy
- Vertisis Custom Pharmacy
- Smith Caldwell Drug Store
- Sixth Avenue Medical Pharmacy
- Dougherty’s Pharmacy
- Triangle Compounding Pharmacy Inc.
- Medisca Inc.
- Wedgewood Pharmacy
- Millers Pharmacy
- Chiron Compounding Pharmacy
- MEDS Canadian Compounding Pharmacy
- Aurora Compounding
- Pace Pharmacy
- Victoria Compounding Pharmacy
- Pratt’s Compounding Pharmacy
- People’s Choice Pharmacy
Request for Methodology@ https://www.persistencemarketresearch.com/methodology/12871
Key Takeaways from Market Study
- CNS agents by product type are leading the animal drug compounding market, and held 35.9% market share in 2021.
- Companion animal segment revenue is expected to increase 2.2X by 2031 accounting for 54.7% market share.
- Oral medication formulations of animal drugs accounted for a market share of over 77% in 2021, owing to blockbuster drug expiries, growing levels of experimentation in drug repackaging, and creation of multiple ingredient combination.
- The North America market for animal drug compounding accounted for 65.2% of the global market share in 2021, and this market is expected to expand at a CAGR of 8.4% through 2031.
“Lower availability of generic substitutes and increasing regulatory compliance are expected to offer market growth opportunities over the coming years,” says an analyst of Persistence Market Research.
Access Full Report@ https://www.persistencemarketresearch.com/checkout/12871
Market Competition
Animal drug compounding market players are adopting new strategies and agreements to expand the production of customized drugs in the market. Manufacturers are also focused on developing currently unavailable pharmaceuticals that fortify market continuity and growth.
- In August 2020, Wedgewood Pharmacy acquired Wildlife Pharmaceuticals and its pharmacy subsidiary ZooPharm. Through this agreement, ZooPharm’s specialized products will be offered to Wedgewood Pharmacy’s veterinary clients.
What Does the Report Cover?
Persistence Market Research offers a unique perspective and actionable insights on the animal drug compounding market in its latest study, presenting historical demand assessment of 2016 – 2021 and projections for 2022 – 2031.
The research study is based on the products (CNS agents, anti-infective agents, hormones and substitutes, anti-inflammatory agents, others), animal type (companion animals, livestock animals), and formulation (injectable, oral, others), across seven key regions (North America, Latin America. Europe, South Asia, East Asia, and Oceania) of the world.
About Us:
Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com